Growth kinetics and self-renewal of human mesenchymal stem cells derived from bone marrow of children with oncohematological diseases during expansion in vitro
- PMID: 16837907
Growth kinetics and self-renewal of human mesenchymal stem cells derived from bone marrow of children with oncohematological diseases during expansion in vitro
Abstract
Aim: We investigated the ability of mesenchymal stem cells (MSCs) derived from bone marrow (BM) of children with oncohematological diseases after chemotherapy and radiation therapy to the self-renewal and proliferation for further expansion and their implementation as co-transplant, together with autologous hemopoietic stem cells (HSCs).
Materials and methods: BM samples from 20 patients with tumors and BM samples from healthy children-donors (for allogenic HSCs transplantation) were under study. The colony forming unit-fibroblast (CFU-F) assay and the colony forming unit-granulocytes and macrophages (CFU-GM) assay were used for the evaluation of MSCs and HSCs proliferative capacity. Mononuclear cells (MNCs) were plated 1 x 10(6). Following 14 days cells subcultured in primary culture (I passage) to study MSCs ability to self-renewal in culture. 6 passages were performed. The population doubling (PD) in each passage and the cumulative population doubling were calculated.
Results: Data revealed 3-4-fold reduction of the mean incidence of CFU-F in patients after treatment compared to donors. The number of CFU-GM in patients was lower than in donors as well (39.0, 9.0-130.0 vs 95.0, 31-205). Correlation between numbers of CFU-F and CFU-GM was revealed in patients BM (r = 0.63, p < 0.003) as well as in healthy children. MSCs from BM possessed high potential to self-renewal. Their number increased 900-fold in primary cultures in the first 14 days and 17-fold in subculture in 60 days. The analysis of cumulative PD in patients and donors demonstrated the slowing of cell proliferation and telomere length decrease from passage to passage.
Conclusion: Despite the low content MSCs from BM of children with oncohematological diseases possessed high potential to self-renewal. The total number of MSCs can be increased 1.5 x 10(4) fold in 2 months period in vitro.
Similar articles
-
Influence of mesenchymal stem cells derived from bone marrow of children with oncohematological diseases on proliferation and self-renewal of hematopoietic progenitor cells in vitro.Exp Oncol. 2008 Jun;30(2):121-8. Exp Oncol. 2008. PMID: 18566575
-
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.Exp Hematol. 1995 Dec;23(14):1520-6. Exp Hematol. 1995. PMID: 8542941
-
Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.Rheumatology (Oxford). 2007 Mar;46(3):403-8. doi: 10.1093/rheumatology/kel267. Epub 2006 Aug 18. Rheumatology (Oxford). 2007. PMID: 16920750
-
Human bone marrow mesenchymal stem cells in vivo.Rheumatology (Oxford). 2008 Feb;47(2):126-31. doi: 10.1093/rheumatology/kem206. Epub 2007 Nov 6. Rheumatology (Oxford). 2008. PMID: 17986482 Review.
-
Different facets of aging in human mesenchymal stem cells.Tissue Eng Part B Rev. 2010 Aug;16(4):445-53. doi: 10.1089/ten.TEB.2009.0825. Tissue Eng Part B Rev. 2010. PMID: 20196648 Review.
Cited by
-
The possible use of stem cells in regenerative medicine: dream or reality?Langenbecks Arch Surg. 2009 Nov;394(6):985-97. doi: 10.1007/s00423-009-0546-0. Epub 2009 Jul 31. Langenbecks Arch Surg. 2009. PMID: 19644703 Review.